Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of frexalimab versus teriflunomide in relapsing multiple sclerosis
2023-504358-36-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing frexalimab with teriflunomide (2 arms). Primary endpoint: Annualized relapse rate during the study period. Planned start Oct 2024; status: authorised.
02
Drugs
frexalimabteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-504358-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504358-36-00.